Thromboxane is a member of the family of
lipids known as
eicosanoids. The two major thromboxanes are
thromboxane A2 and
thromboxane B2. The distinguishing feature of thromboxanes is a 6-membered
ether-containing ring.
Thromboxane is named for its role in blood clot formation (
thrombosis).
Thromboxane is a
vasoconstrictor and a potent hypertensive agent, and it facilitates platelet aggregation.
It is in
homeostatic balance in the
circulatory system with
prostacyclin, a related compound.
The mechanism of secretion of thromboxanes from platelets is still unclear.
They act in the formation of blood clots and reduce blood flow to the site of a clot.
If the cap of a vulnerable plaque erodes or ruptures, as in
myocardial infarction, platelets stick to the damaged lining of the vessel and to each other within seconds and form a plug. These "Sticky platelets" secrete several chemicals, including thromboxane A2 that stimulate vasoconstriction, reducing blood flow at the site.
Role of A2 in platelet aggregation
Thromboxane A2 (TXA2), produced by activated platelets, has prothrombotic properties, stimulating activation of new platelets as well as increasing platelet aggregation.
Platelet aggregation is achieved by mediating expression of the glycoprotein complex
GP IIb/IIIa in the cell membrane of platelets. Circulating
fibrinogen binds these receptors on adjacent platelets, further strengthening the
clot.
Pathology
It is believed that the vasoconstriction caused by thromboxanes plays a role in
Prinzmetal's angina.
Omega-3 fatty acids are metabolized to produce higher levels of TxA3, which is relatively less potent than TxA2 and PGI3; therefore, there is a balance shift toward inhibition of vasoconstriction and platelet aggregation. It is believed that this shift in balance lowers the incidence of myocardial infarction (heart attack) and stroke.
Vasoconstriction and, perhaps, various proinflammatory effects exerted by TxA on tissue microvasculature, is probable reason why the TxA is pathogenic in various diseases, such as ischemia-reperfusion injury.,[3] hepatic inflammatory processes,[4] acute hepatotoxicity [5] etc. TxB2, a stable degradation product of TxA2, plays a role in acute hepatoxicity induced by acetaminophen.[6][7]
Thromboxane inhibitors
Thromboxane inhibitors are broadly classified as either those that inhibit the synthesis of thromboxane, or those that inhibit the target effect of it.
Thromboxane synthesis inhibitors, in turn, can be classified regarding which step in the synthesis they inhibit:
The widely used drug
aspirin acts by inhibiting the ability of the COX enzyme to synthesize the precursors of thromboxane within platelets. Low-dose, long-term aspirin use irreversibly blocks the formation of
thromboxane A2 in
platelets, producing an inhibitory effect on
platelet aggregation. This anticoagulant property makes aspirin useful for reducing the incidence of heart attacks.[8] 40 mg of aspirin a day is able to inhibit a large proportion of maximum thromboxane A2 release provoked acutely, with the prostaglandin I2 synthesis being little affected; however, higher doses of aspirin are required to attain further inhibition.[9]
High-dose
naproxen can induce near-complete suppression of platelet thromboxane throughout the dosing interval and appears not to increase cardiovascular disease (CVD) risk, whereas other high-dose NSAID (non-steroidal-anti-inflammatory) regimens have only transient effects on platelet
COX-1 and have been found to be associated "with a small but definite vascular hazard".[11]
^Ito Y (2003). "Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice". Eur Surg Res. 35 (5): 408–16.
doi:
10.1159/000072174.
PMID12928598.
S2CID40932766.
^Katagiri H (2004). "Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice". Hepatology. 39 (1): 139–150.
doi:
10.1002/hep.20000.
PMID14752832.
S2CID27252438.
^Cavar I (2010). "The role of prostaglandin E2 in acute acetaminophen hepatotoxicity in mice". Histol Histopathol. 25 (7): 819–830.
PMID20503171.
^[1] American Heart Association: Aspirin in Heart Attack and Stroke Prevention "The American Heart Association recommends aspirin use for patients who've had a myocardial infarction (heart attack), unstable angina, ischemic stroke (caused by blood clot) or transient ischemic attacks (TIAs or "little strokes"), if not contraindicated. This recommendation is based on sound evidence from clinical trials showing that aspirin helps prevent the recurrence of such events as heart attack, hospitalization for recurrent angina, second strokes, etc. (secondary prevention). Studies show aspirin also helps prevent these events from occurring in people at high risk (primary prevention)."
[2]
^Tohgi, H; S Konno; K Tamura; B Kimura; K Kawano (1992). "Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin". Stroke. 23 (10): 1400–1403.
doi:
10.1161/01.STR.23.10.1400.
PMID1412574.
S2CID14177039.
^Dockens, RC; Santone, KS; Mitroka, JG; Morrison, RA; Jemal, M; Greene, DS; Barbhaiya, RH (Aug 2000). "Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans". Drug Metabolism and Disposition. 28 (8): 973–80.
PMID10901709.
^Ratti, S; Quarato, P; Casagrande, C; Fumagalli, R; Corsini, A (1998). "Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes". European Journal of Pharmacology. 355 (1): 77–83.
doi:
10.1016/S0014-2999(98)00467-1.
PMID9754941.